Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia  by Ramachandran, Balaji et al.
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a  b  s  t  r  a  c  t
EGCG  (Epigallocatechin-3-gallate)  is the major  active  principle  catechin  found  in  green  tea.  Skepticism
regarding  the safety  of consuming  EGCG  is gaining  attention,  despite  the fact that  it is  widely  being
touted  for  its potential  health  beneﬁts,  including  anti-cancer  properties.  The  lack  of scientiﬁc  data  on
safe  dose  levels  of pure  EGCG  is of  concern,  while  EGCG  has been  commonly  studied  as  a  component  of
GTE  (Green  tea  extract)  and  not  as  a  single  active  constituent.  This  study  has  been  carried out  to  estimate
the  maximum  tolerated  non-toxic  dose  of  pure  EGCG  and  to identify  the  treatment  related  risk  factors.  In
a  fourteen  day  consecutive  treatment,  two  different  administration  modalities  were  compared,  offering
an improved  [i.p  (intraperitoneal)]  and limited  [p.o  (oral)]  bioavailability.  A trend  of dose  and  route
dependant  hepatotoxicity  was  observed  particularly  with  i.p  treatment  and  EGCG  increased  serum  lipidose dependant toxicity
oute dependant toxicity
iver toxicity
yslipidemia
proﬁle  in  parallel  to hepatotoxicity.  Fourteen  day  tolerable  dose  of  EGCG  was established  as  21.1 mg/kg
for  i.p  and  67.8  mg/kg  for  p.o. We  also  observed  that,  EGCG  induced  effects  by both  treatment  routes  are
reversible,  subsequent  to an  observation  period  for  further  fourteen  days  after  cessation  of treatment.  It
was  demonstrated  that  the  severity  of  EGCG  induced  toxicity  appears  to be a function  of dose,  route  of
administration  and period  of  treatment.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
With overwhelming literature, consumption of EGCG
Epigallocatechin-3-gallate) containing preparations in the
orm of GTE (Green tea extract) or puriﬁed preparations, has been
ocumented to show a wide variety of beneﬁcial health effects
uch as prevention of cancer, on obesity, hyperglycemia, dys-
ipidemia, elevated blood pressure, inﬂammation, angiogenesis,
gainst cellular oxidation, [68,76,13], against neurological dis-
ases [44,11,57], arthritis [1], hepatoprotective, against testicular
oxicity, cardiotoxicity [15,80,12,59,38] and to improve insulin
esistance [39]. Due to such numerous favorable health beneﬁts
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
LP, alkaline phosphatase; GTE, green tea extract; i.v, intravenous; i.p, intraperi-
oneal; p.o, oral.
∗ Corresponding author.
E-mail address: balajiphd@gmail.com (B. Ramachandran).
ttp://dx.doi.org/10.1016/j.toxrep.2016.03.001
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and gaining popularity, EGCG is widely marketed as a nutraceutical
supplement.
In spite of this, there is considerable skepticism regarding the
safety of consuming EGCG. Toxicity studies conducted using GTE
or puriﬁed preparations are reported to exhibit potential toxicities
at high doses [4,65], that can provoke nephrotoxicity, aggravated
colitis and colon carcinogenesis, down-regulated expressions of
anti-oxidant enzymes and molecular chaperones. Low and medium
doses of GT polyphenols ameliorated colitis, suppressed down
regulation of self defense proteins [35,21,48,17]. Consumption of
EGCG containing preparations during pregnancy could increase
fetal leukemia risk [35]. Hepatitis and cholestasis are reported as
the most serious adverse effects due to continuous consumption of
huge quantities of green tea or GTE or EGCG capsules, as evidenced
by in vitro, in vivo and clinical reports [29,54,78,32,18]. EGCG con-
sumption could increase intracellular reactive oxygen species and
the effects of EGCG upon cellular oxidation is still uncertain and was
argued both as an anti-oxidant and pro-oxidant [27,81,20]. EGCG
showed strong anti-oxidant activities in vitro. However, such effects
are not consistent and cannot be demonstrated in vivo. EGCG can
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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nduce oxidative stress [35,70] and therefore, can cause adverse
ffects, due to its pro-oxidant activity [43]. Despite such adverse
ffects, the majority of pharmacological actions of EGCG rely on its
ro-oxidant activity such as, to kill cancer cells by forming H2O2
31].
On the other hand, few studies express minimal or no con-
ern; over the genotoxic, teratogenic, reproductive, dermal, acute
nd short term toxic potential of GTE [49,22–24]. More often, the
oxicity of EGCG was studied as a component of GTE or puri-
ed preparations [71,3,19,6,22–24]. Studies with extracts that have
een extracted with standard extraction procedures, show almost
omparable or varied toxicity proﬁle, for e.g., NOAEL’s (no observed
dverse effect level) for two 90 day oral toxicity studies of GTE
n rats and mice, were 500 mg/kg [3,24], 764, 820 mg/kg/day [67],
hile few 28 day oral studies reported a NOAEL of 2000 mg/kg [6],
500 mg/kg/day [19], regardless of slightly varying percentage of
otal EGCG content. Hot water, methanolic, hexane, phenolic and
on-phenolic GT fractions in doses of 500 mg/kg to 2500 mg/kg did
ot cause acute hepatotoxicity [61]. Nevertheless, it is apparent
hat biological effects in the form of NOAEL’s could vary depending
pon the variety of source plant material chosen, the method of
xtraction, on the purity and concentration of the active principle
omponent EGCG and its associated polyphenols being extracted,
uration of the study and hence, cannot represent a reproducible
oxicity scenario [24,72,73,75,19,3,67,47].
Hence, an appropriate characterization of limiting dose,
ioavailability, safe route of exposure, duration of treatment and
he nature of toxicity of the pure active principle EGCG as a single
onstituent, may  allow a better understanding of the potential side
ffects and choosing a dose and dosing frequency that is within
he safety window. Hence, we designed a repeated dose maximum
olerated dose study to assess the dose and route dependant toxi-
ity and other potential treatment related effects with pure EGCG
>98%) ranging from high doses to acceptable intake levels, in two
dministration modalities in adult female swiss albino mice.
. Materials and methods
.1. Chemicals
EGCG was purchased from Cayman chemical company, USA,
MSO (Dimethyl sulfoxide) from MP  Biomedicals, California,
SA and ketamine from Aneket, Neon Laboratories Limited, Pal-
har (Thane), India. Ortho-phosphoric acid (85%), methanol, ethyl
cetate and acetonitrile (HPLC grade) were purchased from Merck.
.2. Experimental animals
Healthy adult female swiss albino mice (around 6 weeks) were
urchased from King Institute of Preventive Medicine, Chennai,
ndia. Animal colonies were housed at the departmental animal
acility in clean polypropylene cages and were fed ad libitum,
ith laboratory rodent diet (Nutrilab® Rodent-IR, Provimi, India).
hroughout the study, animals had free access to fresh potable
rinking water ﬁltered through the aquaguard water ﬁltration sys-
em via feeding bottle. Animals were acclimatised for a period
f two weeks before experimentation. Care of animals complied,
ccording to the regulations of CPCSEA (Committee for the purpose
f Control and Supervision of Experiments on Animals), Ministry
f Environment, Forest and Climate Change, Government of India.
ll animal studies were carried out with prior approval from the
nstitutional Animal Ethics Committee of Cancer Institute (W.I.A),
dyar, Chennai. The animal room was maintained within a temper-
ture range of 22–25 ◦C and a relative humidity of 50 ± 10%. There
as a cycle of 12 h light/dark (lights on at 06:00 AM).y Reports 3 (2016) 336–345 337
2.3. Study design
Dosage was chosen taking into account, the pubchem available
LD50 for EGCG as 2170 mg/kg. One tenth of LD50 was  chosen as
starting higher dose for repeated dose toxicity study; with a default
dose progression factor of 3.2 that corresponds to a dose progres-
sion of one half log unit. Nulliparous, swiss albino mice (around 8
weeks) were randomised into various experimental groups based
on body weight, in all the studies. EGCG was  dissolved in 4% DMSO
diluted in saline as vehicle, irrespective of treatment routes. Var-
ious concentrations of EGCG were freshly prepared, immediately
before the treatment. Control group received mock treatment with
vehicle alone.
Experiment no.1
Animals were grouped into the following experimental groups
(n = 5 per group); control (0), 217, 67.8, 21.1 and 6.6 mg/kg/day and
dosed (100 l volume) through p.o (oral) route of administration
with the aid of gavage needle, for 14 consecutive days followed by
14 days of observation without treatment (total of 28 day study).
Experiment no.2
Animals were grouped into (n = 5 per group); control (0), 108,
67.8, 21.1 and 6.6 mg/kg/day and dosed (100 l volume) either
through p.o or i.p (intraperitoneal) route of administration, with
the aid of disposable 26 G syringe with needle, for 14 consecutive
days followed by immediate sacriﬁce after 24 h of the last dose
(total of 14 day study).
Experiment no.3
Animals were grouped into (n = 5 per group); control (0), 67.8,
21.1 and 6.6 mg/kg/day and dosed (100 l volume) through i.p
route of administration, for 14 consecutive days followed by 14
days of observation without treatment (total of 28 day study).
Whole animal body weight was  measured twice a week
throughout the experiment and the data is expressed as% body
weight change during treatment, in comparison to day 1 body
weight of the same animal, just before the initiation of treatment.
At the end of each study, the animals were fasted overnight, anes-
thetized with ketamine (78 mg/kg, i.p) and sacriﬁced by cervical
dislocation. Whole blood and serum were collected by cardiac
puncture for hematological and biochemical analysis, respectively.
Immediately after sacriﬁce, the animals underwent necropsy. A
gross anatomo-pathological investigation was  carried out before
organ excision. The following organs/tissues have been sampled
for histopathological examination and ﬁxed in 10% neutral buffered
formalin: liver, kidney, stomach, small and large intestines, brain,
spinal cord, spleen, heart, thymus, lungs, trachea, uterus, ovary and
bone marrow. Formalin ﬁxed tissues were parafﬁn embedded, sec-
tioned and stained with haematoxylin and eosin.
2.4. Analysis of complete blood count
Whole blood samples were collected separately in tubes con-
taining EDTA, for the determination of complete haemogram. Hb
(haemoglobin), PCV (packed cell volume), TCRBC (total count of red
blood corpuscles), TCWBC (total count of white blood cells), DC (dif-
ferential count), platelets, MCH  (mean corpuscular haemoglobin),
MCV  (mean corpuscular volume) and MCHC (mean corpuscular
haemoglobin concentration) were analyzed with haematology auto
analyzer MICROS-60, France, as per the manufacturer’s instruc-
tions.
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Table 1
Percentage body weight observed during 14 days consecutive treatment of EGCG followed by 14 days observation period; Doses used are control (0), 217, 67.8, 21.1 and
6.6  mg/kg/p.o. Data expressed as% body weight change in comparison with day1; Mean ± SEM; Data represents Mean ± SEM (n = 5) and * indicates a signiﬁcant difference
from  control, as assessed by one-way ANOVA plus Bonferroni post hoc test (***p < 0.001).
Treatment Control 217 mg/kg/p.o 67.8 mg/kg/p.o 21.1 mg/kg/p.o 6.6 mg/kg/p.o
day 1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
day  18 0.2 ± 0.2 −8.8 ± 1.4*** −3.1 ± 0.7 0.8 ± 1.5 1.7 ± 1.7
day  22 0.4 ± 0.4 −8.0 ± 1.3*** −2.9 ± 0.8 0.8 ± 0.8 0.9 ± 1.5
day  25 0.9 ± 1.5 −8.0 ± 1.3*** −2.9 ± 0.8 0.0 ± 1.2 0.8 ± 0.8
day  28 1.2 ± 0.8 −8.0 ± 1.3*** −2.9 ± 0.8 0.8 ± 0.8 0.9 ± 1.5
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fig. 1. Comparison of plasma levels of EGCG administered through various adminis
fter  a single treatment of 108 mg/kg either through i.v, i.p, p.o route and plotted ag
.5. Analysis of biochemical parameters
For biochemical investigations, the blood samples were col-
ected and allowed to settle down for 10 min  and then centrifuged
t 5000 rpm for 10 min  at 4 ◦C and immediately analyzed. Glu-
ose, urea, creatinine, bilirubin, AST (aspartate aminotransferase),
LT (alanine aminotransferase), ALP (alkaline phosphatase), and
ipid proﬁle (total cholesterol, triglycerides, HDL (high density
ipoprotein) and LDL (low density lipoprotein) cholesterol) were
nalyzed using A25 fully automated biochemical analyzer (Biosys-
ems, Spain), as per the manufacturer’s instructions.
.6. HPLC method development
Swiss albino mice were grouped into three composite groups
n = 5 per group) for each route of administration namely; i.v (intra-
enous), i.p and p.o. All the treatments were done once with
08 mg/kg of EGCG (in a total volume of 100 l). I.v injection was
dministered through lateral tail vein. Immediately after treat-
ent, blood was drawn (not more than 100–120 l per time point),
y retro-orbital survival bleeding from each group at various time
ntervals (0, 0.15, 0.20, 0.30, 0.45, 1, 2, 4, 6, 8, 24 h) post treat-
ent. Each composite group represent, repeated blood withdrawal
rom the same animal for 3 or 4 consecutive time points. Care wasn modalities against time. Data show plasma concentration levels (g/ml) of EGCG
 time and the data represented as Mean ± SEM (n = 5).
taken to ensure adequate haemostasis after each sampling. For the
blood sample, due for the last time point in each composite group,
blood was removed very rapidly after sacriﬁce. Blood was allowed
to settle down for 10 min, centrifuged at 5000 rpm for 10 min  at
4 ◦C. Serum sample (50 l) was  immediately extracted once with
250 l of ethyl acetate and 250 l of acetonitrile, by vortex mix-
ing for 5 min  and centrifuged at 12,000 rpm for 10 min  at 4 ◦C.
The upper organic phase was evaporated to dryness under gen-
tle vacuum drier, the resulting residue was reconstituted in mobile
phase and loaded into Dionex ultimate 3000 model with a qua-
ternary pump delivery system. Separation was  carried out on an
Acclaim 120C-18Column (2.1 × 150 mm,  3 m Dionex) maintained
at 40 ◦C oven temperature, with an isocratic mobile phase com-
posed of methanol-0.1% H3PO4 in water (30:70), 0.2 ml/min ﬂow
rate, reading at max 280 nm.  Primary stock solution was freshly
prepared by dissolving pure EGCG in methanol (5 mg/ml  stock) and
then diluted to 0.05, 0.25, 0.5, 1.25, 2.5, 5.0, and 25.0 g/ml con-
centrations. Serum spiked calibration standards were prepared as:
0.05, 0.1, 0.2, 0.5, 1.0, 2.5, 5.0 and 20.0 g/ml concentrations. The
obtained calibration curves showed a good linearity over the range
of 0.05ug to 25 g/ml for EGCG. The regression equations and their
correlation coefﬁcient (r) were calculated as 0.9998. LOD (limit of
detection) (S/N = 2.8) and LOQ (limit of quantiﬁcation) (S/N = 13.6)
were determined as 5 and 50.0 ng/ml for EGCG. Stability of serum
B. Ramachandran et al. / Toxicolog
Table  2
Measurement of circulating plasma levels of EGCG at various time points post treat-
ment with i.v, i.p and p.o routes of administration. Data expressed as mean estimates
for various pharmacokinetic parameters.
Parameter Unit Mean estimated values
i.v i.p p.o
AUC0–t h mg/l 5.96 1.87 0.40
AUC0–inf h mg/l 6.22 1.90 0.47
AUMC0–t h mg/l 8.96 3.14 1.13
AUMC0–inf h mg/l 9.23 3.30 1.33
MRT  hour 1.48 1.74 2.86
t1/2 minutes 11.40 53.40 68.40
Tmax minutes 10.00 45.00 45.00
Cmax g/ml 8.63 2.10 0.14
peak.concn uM 18.84 4.56 0.30
Tlast minutes 480.00 360.00 360.00
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PClast g/ml 0.06 0.00 0.06
Bioavailability % 100.00 31.37 6.71
xtracted EGCG was analyzed at two different storage conditions;
amples were kept in room temperature or 4 ◦C for 4 days and re-
nalyzed, the concentration obtained was compared with the initial
oncentration. The relative content of EGCG was >95% at 4 ◦C and
88% at room temperature.
.7. Statistics
Statistical analysis (explained in ﬁgure legends) was performed
sing GraphPad Prism version 5.01 for Windows, GraphPad Soft-
are (San Diego, California, USA). The same was used to generate
gures and graphics. Data expressed as mean ± standard error
ean (SEM). Standard pharmacokinetic metric equations were
sed to calculate various pharmacokinetic parameters, assuming
s non-compartmental model.
. Results
.1. Effect of repeated p.o treatment of EGCG for 14 consecutive
ays followed by 14 days of observation period
We  evaluated the effect of EGCG by p.o treatment in a range of
oses used: control (0), 217, 67.8, 21.1 and 6.6 mg/kg/p.o once daily
or 14 consecutive days, followed by 14 days observation without
reatment (total 28 day study). Adult female swiss albino mice was
hosen throughout the study, since it is the most commonly used
train for toxicological studies. Animals in 217 mg/kg/p.o group,
howed an 8.8% decrease (day 18) in body weight, post treatment
ersus 10% limit (IUPAC (International Union of Pure and Applied
hemistry) deﬁnition) (Table 1). Histopathological examination of
elected tissues, measurement of hematological and biochemical
arameters at the end of the study (day 28) did not show any major
reatment related changes (data not shown). However, based on the
ecrease in body weight of 8.8%, 217 mg/kg dose was discarded and
0% (108 mg/kg) of the dose was taken forward for further studies.
.2. Measurement of peak plasma levels of EGCG in response to
arious administration modalities
Circulating plasma levels of EGCG could vary, depending upon
he route of administration that affects bio-absorption, distribu-
ion, metabolism and excretion and in turn ultimately, inﬂuence
he overall toxicity. With a single treatment of 108 mg/kg of EGCG,
ioavailability was compared between i.p and p.o route of treat-
ent, against i.v route. Plasma levels of EGCG was measured
t 0, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480 and 1440 min.
eak plasma concentration was obtained at 10, 45, 45 min  for i.v,y Reports 3 (2016) 336–345 339
i.p and p.o route of treatments respectively (Fig. 1). EGCG was
rapidly detected in serum by i.v (AUC0–t = 5.96), followed by i.p
route (AUC0–t = 1.87). p.o route has shown the least bioavailabil-
ity (AUC0–t = 0.40) (Table 2), and the drug was cleared within 24 h,
by all routes of administration. We  arrived to a more obvious con-
clusion, that EGCG was  more bioavailable through i.p route of 31%
compared to p.o route of 6.7%.
3.3. Comparison of EGCG induced effects by p.o versus i.p
treatment for 14 consecutive days
EGCG was  dosed in two  different administration modalities (i.p
versus p.o), in a range of doses namely; control (0), 108, 67.8, 21.1
and 6.6 mg/kg consecutively for a period of 14 days. At the end
of the study, 21.1, 67.8 and 108 mg/kg/i.p dosing but not p.o dos-
ing, signiﬁcantly decreased animal body weight by −4.4, −9.9 and
−30.3% respectively, in comparison to controls versus 10% MTD
IUPAC limit (Table 3). We  did not observe any difference in feed
consumption, between the mock treated controls and treatment
groups. Since animals were maintained in cages of 5 mice each,
we measured the entire amount of food and water used daily by
the group and normalized to a single animal. Animal mortality was
observed in both 108 and 67.8 mg/kg/i.p treatment groups, starting
from day 3 of treatment. All animals in 108 mg/kg/i.p died, around
day 8 of the study and all animals in 67.8 mg/kg/i.p group died
by day 16 of the study. I.p treatment in a dose dependant fash-
ion, clearly increased serum markers of bilirubin, AST, ALT, ALP to
a maximum at 108 mg/kg/i.p with a signiﬁcant increase of +414,
+783, +430, +204% respectively, compared to corresponding con-
trols. AST and ALT has shown a signiﬁcant increase of +212 and
+165% respectively, with 67.8 mg/kg/i.p, when compared to con-
trols. P.o treatment has not shown any dose dependant changes,
with an exception, that ALT marker was appreciably increased
with 108 mg/kg/p.o. Serum urea was signiﬁcantly decreased only in
108 mg/kg/i.p (Fig. 2). Histopathological analysis was carried out in
a range of tissues extracted 24 h, after the last dose of 14 days treat-
ment. Liver was  the only organ that showed toxicity in i.p treatment
with increasing dose, ranging from mild congestion to severe acute
hepatitis (Fig. 3). With regard to p.o treatment, only mild changes
pertaining to hepatotoxicity was  noted and was  more evident with
108 mg/kg/p.o treatment. With an intention to see if other organs
are targets of EGCG induced toxicity, we  analyzed kidney, stomach,
small and large intestines, brain, spinal cord, spleen, heart, thymus,
lungs, trachea, uterus, ovary and bone marrow, which did not show
any treatment related toxicity.
Concerning the effect of EGCG treatment on lipid proﬁle, i.p
treatment displayed a pattern of dose dependant increase in
triglycerides, serum LDL and total cholesterol, at a noteworthy
increase of +100, +197 and + 88% respectively versus controls, in
108 mg/kg/i.p treatment group. Serum LDL was increased to +141%
with 67.8 mg/kg/i.p treatment. With 108 mg/kg/p.o treatment, no
dose dependant changes were observed, except, with an increase
of triglycerides to +58%, compared against control. Serum HDL and
blood glucose levels remained unaltered in our experimental con-
ditions (Fig. 2). We  did not observe any signiﬁcant treatment related
changes in hematological parameters with both treatment routes.
Overall, 108 mg/kg/i.p signiﬁcantly increased serum markers of
liver damage and lipid proﬁle. Based on decrease in body weight
in response to treatment, 108 and 67.8 mg/kg doses are considered
to be toxic by i.p treatment and 21.1 mg/kg/i.p was taken as 14 day
maximum tolerated dose via i.p route. With regard to p.o treatment,
we observed mild changes in response to 108 mg/kg/p.o. Hence, we
estimated 67.8 mg/kg as 14 day maximum tolerated dose via p.o
route.
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Table 3
Comparison of percentage body weight observed during 14 days consecutive i.p or p.o treatment of EGCG. Doses used are control (0), 108, 67.8, 21.1 and 6.6 mg/kg/i.p or p.o.
Data  represents Mean ± SEM (n = 5) and * indicates a signiﬁcant difference from control, as assessed by one-way ANOVA plus Bonferroni post hoc test (*p < 0.05), (**p < 0.01),
(***p < 0.001). †  indicates mortality post treatment.
Treatment Control 108 mg/kg 67.8 mg/kg 21.1 mg/kg 6.6 mg/kg
i.p p.o i.p p.o i.p p.o i.p p.o
day 1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
day  4 0.5 ± 0.6 −7.6 ± 2.8 −0.3 ± 0.6 −0.4 ± 1.1 −0.9 ± 0.7 −0.9 ± 1.8 −0.6 ± 1.8 0.4 ± 1.0 0.0 ± 2.6
day  8 0.4 ± 1.4 −30.3 ± 2.0*** −2.3 ± 1.5** −6.6 ± 2.2 ** 0.7 ± 1.6 −3.4 ± 1.8 * 0.0 ± 1.6 −0.8 ± 2.2 2.7 ± 3.0
day  11 0.0 ± 1.6 †  −2.6 ± 0.9 * −4.7 ± 2.2 ** −0.4 ± 0.8 −3.5 ± 1.8*** 1.0 ± 2.2 0.8 ± 1.6 0.0 ± 0.0
day  15 0.5 ± 1.0 †  −3.4 ± 1.4 −9.9 ± 2.9*** −1.7 ± 0.5 −4.4 ± 2.2*** 0.4 ± 2.8 1.9 ± 4.4 0.3 ± 0.5
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rig. 2. Effect of 14 day repeated treatment of EGCG by i.p versus p.o route in a rang
ndicates a signiﬁcant difference from control, as assessed by one-way ANOVA plus
.4. Effect of i.p treatment of EGCG for consecutive 14 days
ollowed by 14 days observation period
In order to check the reversibility, persistence or delayed occur-
ence of toxic effects, animals post i.p treatment of 14 days were
aintained without treatment for an additional 14 days and body
eight was followed (Table 4). Due to severe toxicity, we did not
nclude 108 mg/kg/i.p treatment group in this experiment. Group
ith 67.8 mg/kg dose was also excluded from the experiment,
ecause of the noted mortality. During the observation period,
1.1 and 6.6 mg/kg/i.p improved body weight gain. At the end of
he study, histological, biochemical and hematological parameters
nalyzed, did not show any changes (data not shown) in response
o treatment, when compared against control. This indicates that,
GCG induced changes are reversible upon cessation of treatment.. Discussion
The present study was designed to investigate the dose and
oute dependant toxicity and other potential treatment relatedoses, on various biochemical parameters. Data represents Mean ± SEM (n = 5) and *
rroni post hoc test (*p < 0.05), (**p < 0.01), (***p < 0.001).
toxic effects with repeated dosing of pure EGCG (98%), for a period
of 14 consecutive days and also to check the persistence of toxicity
by observation for further 14 days, without treatment. The study
demonstrates that, the toxic effects of EGCG corresponds to plasma
bioavailability per se route of administration and shows that, tox-
icity induced by EGCG at lower doses is transient and reversible,
subsequent to cessation of treatment. Moreover, the study for the
ﬁrst time, to the best of our knowledge, demonstrates that repeated
dosing of pure EGCG could lead to dyslipidemia, in parallel to hep-
atotoxicity. Our data adds to the incredulity of EGCG safety and
suggests that caution should be taken care, when consuming EGCG
as pure compound and especially contraindicated for parentral
applications.
4.1. EGCG induced toxicity corresponds to plasma bioavailability
and route of administrationWe  compared two  different administration modalities (p.o and
i.p route) for a consecutive period of 14 days with the same range
of dosages, to check the potency of toxic effects of EGCG in a
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Fig. 3. Photo micrographs (at 10X) of liver sections showing dose dependant toxic changes in response to 14 day consecutive treatment of EGCG. (a) Normal liver parenchyma;
(b)  fatty change with moderate lobular inﬂammation (arrow); (c) mildly congested liver (box); (d) mild periportal and mild lobular inﬂammation (arrow), mild kupfer
cell  hyperplasia. Mild ballooning degeneration (arrow head), focal acute inﬂammation; (e) congested liver with very mild periportal inﬂammation (arrow); (f) moderate
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periportal and mild lobular inﬂammation, with fatty change (arrow); (g) congeste
cute  inﬂammation, ballooning degeneration of hepatocytes (arrow), hepatocyte d
upfer  cell hyperplasia and congestion, mild to moderate periportal inﬂammation (
ondition of decreased (p.o route) and increased bioavailability
i.p route). We  chose i.p route instead of i.v, as a parentral route
ue to practical feasibility of i.p administration, during repeated
ose studies. In our chosen doses, i.p treatment clearly increased
erum markers of liver damage and lipid proﬁle in a dose depen-
ant fashion and the observed effects are more prominent with
.p, than p.o treatment. In case of p.o treatment, hepatotoxicity
nd changes in serum lipid proﬁle were seen well evident only
n the highest dose of 108 mg/kg/p.o. With a single p.o treatment,
 peak plasma concentration of 0.30 M of EGCG was attained,
hich is closer to a physiologically achievable serum EGCG con-
entration of not higher than 1 M [79]. In case of i.p treatment, a
eak plasma concentration of 4.56 M was attained and this falls
ithin the pharmacological range of <1–100 M of EGCG, to poten-
ially favor some biological activity [33,53]. This could be ascribed,
ue to basic differences in bioavailability with p.o and i.p treat-
ent. The reason, we did not observe major toxicity changes with
.o route of treatment, could be due to its limited bioavailabil-
ty. It is known that orally administered EGCG is modiﬁed and
etabolized in the digestive system, prior to be absorbed from the
ntestines into the systemic circulation or excreted [62]. On the
ther hand, with i.p treatment the drug gets absorbed through two
odes of absorption, the visceral peritoneal linings with rich bloodessels/capillaries, absorbs the drug and passes through portal cir-
ulation; the parietal peritoneum has blood vessels/capillaries that
rain into systemic circulation. The other mode is through lym-
hatics, which the peritoneum has in plenty and absorption ofr with fatty change (box); (h) congested liver parenchyma with moderate lobular
ut areas (star), kupfer cell proliferation and calciﬁcation (acute hepatitis); (i) mild
).
drug through lymphatics, pass onto the systemic circulation. We
chose i.p treatment due to the reason that, catechins are known
to show poor bioavailability by oral route and undergo extensive
biotransformation, direct routes of administration such as i.p could
offer a higher bioavailability to understand the potential biologi-
cal activity. We also veriﬁed by two independent experiments for
each treatment modality, if the observed toxic effects are tran-
sient and subside, subsequent to cessation of treatment. In order
to understand the recovery, persistence and reversibility of EGCG
induced effects, the treatment was  carried out for 14 consecutive
days by either routes of administration and followed for a observa-
tion period of further 14 days, without treatment (total 28 days of
study). At the end of the study, it was  found that the identiﬁed toxic-
ities for the chosen doses, to be completely regressed in either of the
treatment routes and this indicates that EGCG toxicity is reversible,
post withdrawal of treatment. This could be due to the absence of
EGCG in circulation to elicit the necessary pharmacological activ-
ity and the capacity of liver to undergo rapid repair mechanisms.
Although, it has to be noted that the betterment of toxic effects in
the form of improvement of decreasing body weight was observed,
only for the chosen lower dose ranges (21.1 and 6.6 mg/kg/i.p).
The current data indicate a comprehensive picture of poten-
tial target or non- target organs of toxicity induced by repeated
doses of EGCG, by p.o and i.p treatment and also signify that cau-
tion should be exercised for parentral application of EGCG and
inadvertent consumption of EGCG containing preparations [45].
However, routine habitual consumption of EGCG in the form of
342 B. Ramachandran et al. / Toxicolog
Table 4
Percentage body weight observed during 14 days consecutive treatment of EGCG
followed by 14 days observation period; doses used are control (0), 67.8, 21.1 and
6.6  mg/kg/i.p. Data expressed as% body weight change in comparison with day1;
Mean ± SEM (n = 5). †  indicates mortality post treatment.
Treatment Control 67.8 mg/kg/i.p 21.1 mg/kg/i.p 6.6 mg/kg/i.p
day 1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
day  18 0.2 ± 2.6 †  −2.2 ± 1.3 0.2 ± 2.0
day  22 0.6 ± 1.5 †  1.1 ± 2.0 1.5 ± 2.3
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oday  25 0.6 ± 1.5 †  1.1 ± 2.0 1.3 ± 3.0
day  28 1.1 ± 1.7 †  1.1 ± 2.0 1.3 ± 3.0
raditional green tea with the presence of natural leaf matrix con-
aining ﬂavones, tannins and other green tea derived compounds
ffering limited bioavailability would be better compared to intake
f pure EGCG capsules as dietary supplements [3]. Oral ingestion
f modest amounts of EGCG in the physiological range of not more
han 1uM, was well known to induce beneﬁcial effects [79].
.2. Maximum tolerated dose levels of EGCG
EGCG toxicity was widely studied by many groups, either in
ure form or as a component of GTE or puriﬁed preparations
t various dose levels, routes of administration and study dura-
ion, as summarized below. It has been shown that a single dose
f EGCG (100% purity) at 1500 mg/kg, p.o dramatically increased
lasma ALT and reduced 85% of survival of CF-1 mice. Whereas,
wo once daily doses of 500 and 750 mg/kg/p.o resulted in a 20% and
5% decrease of survival, respectively. Moderate to severe hepatic
ecrosis was observed and the hepatotoxicity was associated with
xidative stress; with increased hepatic lipid peroxidation, plasma
-isoprostane, hepatic metallothionein and gamma-histone 2AX
rotein expression [32]. Single dose of 2000 mg/kg/p.o of 90%
ure EGCG preparation was lethal to rats; while, a single dose
f 200 mg/kg revealed no toxicity. In another study, 50, 150 and
00 mg/kg/day repeated administration through diet for 13 weeks
>77% of EGCG content) to rats induced no toxicity [24]. EGCG con-
aining extract (85% purity) administered to mice at a dose of 50 and
5 mg/kg/i.p/day, for 3 consecutive days or 3 times a week for eight
eeks, were shown as effective doses without increased morbidity.
n particular, 50 mg/kg/i.p was found to be the lowest effective dose
o improve liver injury without causing adverse effects [5,69]. In
nother study with pure EGCG, a single 100 mg/kg/i.p signiﬁcantly
ncreased serum ALT levels but not mortality within 24 h. A sin-
le treatment with 150 and 300 mg/kg/i.p led to mortality of male
D-1 mice, in less than 24 h of treatment [14] and male CF-1 mice,
reated once with 200 and 400 mg/kg/i.p, 4 out of 5 mice died in 2–3
ays and less than 24 h, respectively [62]. Wistar albino rats were
rally treated with 100 and 500 mg/kg/p.o/day of GTE for 30 days [2]
eporting no toxicity. Nevertheless, in this study [2], EGCG content
rom aqueous extract is not indicated. In another report, a single
ethal dose of 200 mg/kg/i.p of EGCG (>98% purity) triggered hepa-
otoxicity, suppressed major antioxidant enzymes and Nrf2 rescue
athway, a non-lethal dose of repeated 75 mg/kg/i.p/day treat-
ent for 5 consecutive days, markedly decreased the anti-oxidant
nzymes and activated the Nrf2 rescue response, while a consec-
tive 7 day MTD  of 45 mg/kg/i.p/day did not reproduce the above
hanges [74]. The doses chosen by the above reports, corresponds
o a practically unfeasible dose, ranging from 140 (2,000) > 105
1500) > 52.5 (750) > 35 (500) > 28 (400) > 21 (300) > 14 (200) > 10.5
150) > 7 (100) > 5.25 (75) > 3.5 (50) and 3.1 (45) g/day (mg/kg study
ose) of exposure for a 70 kg human. All the studies reported above,
se very high doses of either pure EGCG or GTE and it is not pos-
ible to either compare or corroborate the effects obtained with
ure compound or as a component of an extract. Because, it is obvi-
us that in an extract; there are other associated compounds thaty Reports 3 (2016) 336–345
cross react with the principle component and may  either synergize
or antagonize the effects of the principle component [3]. Caffeine
free EGCG of 0.8 g, as capsule for 4 weeks with >60% increase of
free EGCG in plasma, was regarded as safe and well tolerated in
healthy human subjects and this accounts to 11.4 mg/kg/day/p.o
of exposure [8,9]. In the current study, we  discarded the idea of
using very high doses of EGCG. Swiss albino mice was treated with
a range of doses; control (0), 108, 67.8, 21.1 and 6.6 mg/kg/day for
a period of 14 days which accounts to an exposure of 0, 7.5, 4.7, 1.4
and 0.46 g/day for a 70 kg human. The tolerated range of 0.8 g/day
[8,9] falls within the range of our chosen doses and indeed, through
p.o route of treatment, we did not observe major toxicity changes
close to this range of treatment groups (21.1 to 6.6 mg/kg/p.o).
Our selected dosages were milder and represent a broad range;
from pharmacologically irrelevant to daily tolerable doses, that are
safe for human consumption (108 mg–6.6 mg/kg/day exposure).
We observed only liver toxicity in our experimental conditions
and not in other tissues such as kidney, stomach and intestines,
observed by others [24,35,32]. Based on decrease in body weight
and EGCG induced changes in serum chemistry, the 14 day max-
imum tolerable dose of EGCG was  estimated as 21.1 mg/kg for i.p
and 67.8 mg/kg for p.o.
4.3. Effect of EGCG treatment on serum lipid proﬁle
EGCG is well known to sustain weight loss, improve serum
lipid proﬁle [77,16,58] and systolic blood pressure [50], to pro-
tect against oxidation of plasma LDL [46]. In contrast, there is
also modest information that does not support the association of
EGCG consumption, connected to a favorable decrease in serum
lipids [70,10]. EGCG may  promote steatosis and not suitable for
decreasing plasma lipids [37]. In one clinical study, administer-
ing EGCG capsule or GTE with a per day consumption of 366
and 970 mg respectively, appeared to decrease serum lipid pro-
ﬁle for the initial 15 days as a acute effect, but this effect was
not persistent after 30 days of continuous consumption, in both
healthy and slightly hypercholesterimic volunteers [56]. Of partic-
ular interest, in parallel to increase in EGCG dosage, we observed
a pattern of dose dependant increase in serum triglycerides, LDL
and total cholesterol. While, HDL cholesterol remain unchanged in
our experimental conditions. We  explored the literature if EGCG
targets and down regulates PPAR (alpha and beta) as a key reg-
ulator of lipid metabolism [28]. But, it was ruled out that EGCG
is a PPAR – alpha ligand and activate hypolipidemic PPAR- alpha
and inhibit adipogenic PPAR – gamma  [36]. Indeed, It was  evi-
dent that malfunction of liver is linked to increase in serum lipid
proﬁle. In one study, polychlorinated biphenyls induced hepatotox-
icity associated with increase in LDL, triglycerides and cholesterol
after 30 days of continuous treatment [63]. Several authors have
observed a pattern of increased lipid proﬁle in response to drug
induced liver toxicity [55,40]. The reason for an increase in lipid
proﬁle, during liver damage for e.g., damage induced by CCl4, the
imbalance of LDL could be a possibility due to impaired lipopro-
tein metabolism that could interfere with the normal process of
synthesis, secretion and removal of lipoproteins [41,30]. The other
likelihood is that during drug induced hepatotoxicity, there is a high
oxidative stress that damage liver, which in turn deregulate the
production of lipid macromolecules and associated dyslipidemia
[42]. Therefore, this could be one of the reasons for increased LDL
and to a certain extent on triglycerides and total cholesterol in our
experimental conditions and others [7,66]. EGCG in a similar pat-
tern to dyslipidemia observed by us, exerts both glucose tolerance
and intolerance [51,25], a inﬂammatory response instead of anti-
inﬂammatory activity [52]. Infact, the study [25] clearly points out
that lower dose of green tea is anti-diabetic while, a higher dose
is diabetogenic and further indicated the hypolipidemic effect of
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reen tea in their experimental conditions. Therefore, we conclude
hat, the observed effects of EGCG could be due to a function of
ose dependant response [25,60]. In the present study, EGCG is
dministered as a pure substance and not embedded in any matrix.
e observed that pure EGCG increased LDL, total cholesterol, but
e cannot make out, if EGCG embedded in a matrix, may  cause
he same observation, which is beyond the scope of the study and
emains to be elucidated. We  are unable to propose any mecha-
ism and can only arrive at speculations, that EGCG in higher doses,
ere signiﬁcant hepatotoxicity was also observed in parallel could
isrupt the equilibrium of serum lipid proﬁle by unknown mecha-
isms and there is a probable risk of developing dyslipidemia with
hronic consumption of EGCG.
.4. Mice as a suitable model to study EGCG toxicity
In the current study, we selected mouse as a study model,
nstead of rats due to increased sensitivity of mice, to respond
o EGCG toxicity. This is due to the fact that, rats have poor
ioavailability to EGCG compared to mice, and mice and humans
ave higher and comparable bioavailability for EGCG; in terms
f plasma availability and biotransformation than those of rats
34,32,44,26]. A comprehensive study, [3] highlighted the sen-
itivity difference between rats and mice that undergo gavage
reatment of 1000 mg/kg of GTE, 5 days a week, for 14 weeks. This
tudy [3] showed that mice are more susceptible to EGCG toxic-
ty, compared to rats. Rats appeared to be resistant to treatment
elated mortality, while with mice, mortality was  observed during
he course of the study. Histopathological changes due to treat-
ent were observed in both species in liver, nasal sinus, mesenteric
ymph nodes and thymus gland. In mice, the affected organs were
xtended to peyer’s patches, spleen and mandibular lymph nodes.
oreover, the study [3] points out to a gender difference of female
ice and rats, being increasingly susceptible to hepatotoxicity,
hen compared to males and males are more vulnerable, towards
ecreased body weight gain. Although, another study reports that
here is no gender difference in animals and humans in terms of
lasma EGCG availability [26]. A study, administered 50, 150 and
00 mg/kg/day of 77% EGCG preparation for 13 weeks, but no mor-
ality or signs of toxicity were noted during the treatment and
ecovery periods. In the same study, both female and male rats
ere treated with a single dose of 2000 mg/kg of Teavigo (93%
GCG) preparation, most of the treated animals died within 72 h
f treatment and pathological changes were noted in stomach and
ntestine [24]. In the current study, in both i.p and p.o routes of
reatment with 108 mg/kg/day dose of >98% pure EGCG for 14 days,
e observed abnormalities only in the liver, but not in other organs
uch as kidney, intestine, thymus and spleen which is in agreement
ith Lambert et al. [32] that studied a single dose of 1500 mg/kg/p.o
f 100% pure EGCG. The discrepancies in the observations, between
he studies, could be probably due to the fundamental differences
n treatment with pure EGCG or with GTE, species and the dura-
ion of exposure. A similar pattern of species difference and length
f exposure was observed, in case of the ability of EGCG to afford
europrotection [44].
In conclusion, in our experimental conditions of 14 day con-
ecutive dosing by both conventional (p.o) and unconventional
outes of administration (i.p), we have observed that the major
reen tea polyphenol, EGCG (>98% purity) to show hepatotoxic-
ty and to increase serum lipid proﬁle. To our knowledge, in none
f the studies, that veriﬁed hepatotoxicity measured serum levels
f lipids. We  show for the ﬁrst time that EGCG treatment, achiev-
ng appreciable plasma concentrations is likely to increase serum
ipids in parallel, to the severity of liver damage. This study is a proof
f an obvious notion, that dietary compound, as pure compounds
an exert harmful effects at increased pharmacological doses. Con-
[y Reports 3 (2016) 336–345 343
versely, we cannot exactly explain the mechanism of association
between EGCG, liver and serum lipids, which needs to be further
elucidated. We  encourage, that more animal and controlled clinical
studies needs to be conducted in this regard, to further verify the
safety of GTE, EGCG containing preparations or pure EGCG capsules.
Conﬂict of interest
The authors report no declarations of interest.
Transparency document
The Transparency document associated with this article can be
found in the online version.
Acknowledgements
This work was  supported by Science and Engineering Research
Board (SB/YS/LS-49/2013) to RB. The authors wish to thank
Dr. R. Arivazhagan for his help in biochemical analysis and S.
Namachivayam for his excellent technical assistance.
References
[1] S. Ahmed, Green tea polyphenol epigallocatechin 3-gallate in arthritis:
progress and promise, Arthritis Res. Ther. 122 (2010) 208.
[2] M.  Chakraborty, J.V. Kamath, Pharmacodynamic interaction of green tea
extract with hydrochlorothiazide against ischemia-reperfusion
injury-induced myocardial infarction, J. Adv. Pharm. Technol. Res. 53 (2014)
134–139.
[3] P.C. Chan, Y. Ramot, D.E. Malarkey, P. Blackshear, G.E. Kissling, G. Travlos, A.
Nyska, Fourteen-week toxicity study of green tea extract in rats and mice,
Toxicol. Pathol. 387 (2010) 1070–1084.
[4] P.Y. Chang, J. Mirsalis, E.S. Riccio, J.P. Bakke, P.S. Lee, J. Shimon, S. Phillips, D.
Fairchild, Y. Hara, J.A. Crowell, Genotoxicity and toxicity of the potential
cancer-preventive agent polyphenon E, Environ. Mol. Mutagen. 411 (2003)
43–54.
[5] J.H. Chen, G.L. Tipoe, E.C. Liong, H.S. So, K.M. Leung, W.M.  Tom, P.C. Fung, A.A.
Nanji, Green tea polyphenols prevent toxin-induced hepatotoxicity in mice
by  down-regulating inducible nitric oxide-derived prooxidants, Am.  J. Clin.
Nutr. 803 (2004) 742–751.
[6] C.P. Chengelis, J.B. Kirkpatrick, K.S. Regan, A.E. Radovsky, M.J. Beck, O. Morita,
Y.  Tamaki, H. Suzuki, 28-Day oral gavage toxicity studies of green tea
catechins prepared for beverages in rats, Food Chem. Toxicol. 463 (2008)
978–989.
[7] C.Z. Christine, B.W. Hilary, Rooibos Herbal Tea Linked to Hepatotoxicity and
Severe Hypercholesterolemia, 2013 (accessed 03.11.15) Available online at:
https://endo.confex.com/endo/2013endo/webprogram/Paper8510.html.html.
[8] H.H. Chow, Y. Cai, I.A. Hakim, J.A. Crowell, F. Shahi, C.A. Brooks, R.T. Dorr, Y.
Hara, D.S. Alberts, Pharmacokinetics and safety of green tea polyphenols after
multiple-dose administration of epigallocatechin gallate and polyphenon E in
healthy individuals, Clin. Cancer Res. 99 (2003) 3312–3319.
[9] H.H. Chow, I.A. Hakim, D.R. Vining, J.A. Crowell, J. Ranger-Moore, W.M.  Chew,
C.A. Celaya, S.R. Rodney, Y. Hara, D.S. Alberts, Effects of dosing condition on
the oral bioavailability of green tea catechins after single-dose administration
of  Polyphenon E in healthy individuals, Clin. Cancer Res. 1112 (2005)
4627–4633.
10] S. Ellinger, N. Müller, P. Stehle, G. Ulrich-Merzenich, Consumption of green tea
or green tea products: is there an evidence for antioxidant effects from
controlled interventional studies? Phytomedicine 1811 (2011) 903–915.
11] N. Ferreira, M.J. Saraiva, M.R. Almeida, Epigallocatechin-3-gallate as a
potential therapeutic drug for TTR-related amyloidosis: in vivo evidence from
FAP mice models, PLoS One 71 (2012) e29933.
12] R.N. Fiorini, J.L. Donovan, D. Rodwell, Z. Evans, G. Cheng, H.D. May, C.E.
Milliken, J.S. Markowitz, C. Campbell, J.K. Haines, M.G. Schmidt, K.D. Chavin,
Short-term administration of -epigallocatechin gallate reduces hepatic
steatosis and protects against warm hepatic ischemia/reperfusion injury in
steatotic mice, Liver Transpl. 113 (2005) 298–308.
13] M.  Friedrich, K.J. Petzke, D. Raederstorff, S. Wolfram, S. Klaus, Acute effects of
epigallocatechin gallate from green tea on oxidation and tissue incorporation
of dietary lipids in mice fed a high-fat diet, Int. J. Obes. Lond. 365 (2012)
735–743.
14] G. Galati, A. Lin, A.M. Sultan, P.J. O’Brien, Cellular and in vivo hepatotoxicity
caused by green tea phenolic acids and catechins, Free Radic. Biol. Med. 404
(2006) 570–580.
15] J. Ge, B. Han, H. Hu, J. Liu, Y. Liu, Epigallocatechin-3-O-gallate protects against
hepatic damage and testicular toxicity in male mice exposed to
di-2-ethylhexyl phthalate, J. Med. Food 187 (2015) 753–761.
3 icolog
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[44 B. Ramachandran et al. / Tox
16] A. Gokulakrisnan, B. Jayachandran Dare, C. Thirunavukkarasu, Attenuation of
the cardiac inﬂammatory changes and lipid anomalies by
(-)-epigallocatechin-gallate in cigarette smoke-exposed rats, Mol. Cell.
Biochem. 354 (1-2) (2011) 1–10.
17] F. Guan, A.B. Liu, G. Li, Z. Yang, Y. Sun, C.S. Yang, J. Ju, Deleterious effects of
high concentrations of (-)-epigallocatechin-3-gallate and atorvastatin in mice
with colon inﬂammation, Nutr. Cancer 646 (2012) 847–855.
18] P. Hirsova, G. Karlasova, E. Dolezelova, J. Cermanova, M.  Zagorova, Z. Kadova,
M.  Hroch, L. Sispera, P. Tomsik, M.  Lenicek, L. Vitek, P. Pavek, O. Kucera, Z.
Cervinkova, S. Micuda, Cholestatic effect of epigallocatechin gallate in rats is
mediated via decreased expression of Mrp2, Toxicology 303 (2013) 9–15.
19] Y.W. Hsu, C.F. Tsai, W.K. Chen, C.F. Huang, C.C. Yen, A subacute toxicity
evaluation of green tea Camellia sinensis extract in mice, Food Chem. Toxicol.
4910 (2011) 2624–2630.
20] S. Inami, M.  Takano, M.  Yamamoto, D. Murakami, K. Tajika, K. Yodogawa, S.
Yokoyama, N. Ohno, T. Ohba, J. Sano, C. Ibuki, Y. Seino, K. Mizuno, Tea catechin
consumption reduces circulating oxidized low-density lipoprotein, Int. Heart
J.  486 (2007) 725–732.
21] H. Inoue, M.  Maeda-Yamamoto, A. Nesumi, T. Tanaka, A. Murakami, Low and
medium but not high doses of green tea polyphenols ameliorated dextran
sodium sulfate-induced hepatotoxicity and nephrotoxicity, Biosci. Biotechnol.
Biochem. 776 (2013) 1223–1228.
22] R.A. Isbrucker, J. Bausch, J.A. Edwards, E. Wolz, Safety studies on
epigallocatechin gallate EGCG preparations. Part 1: genotoxicity, Food Chem.
Toxicol. 445 (2006) 626–635.
23] R.A. Isbrucker, J.A. Edwards, E. Wolz, A. Davidovich, J. Bausch, Safety studies
on epigallocatechin gallate EGCG preparations: part 3: teratogenicity and
reproductive toxicity studies in rats, Food Chem. Toxicol. 445 (2006) 651–661.
24] R.A. Isbrucker, J.A. Edwards, E. Wolz, A. Davidovich, J. Bausch, Safety studies
on epigallocatechin gallate EGCG preparations Part 2: dermal, acute and
short-term toxicity studies, Food Chem. Toxicol. 445 (2006) 636–650.
25] M.S. Islam, H. Choi, Green tea: anti-diabetic or diabetogenic: a Dose response
study, Biofactors 291 (2007) 45–53.
26] S. Kim, M.J. Lee, J. Hong, C. Li, T.J. Smith, G.Y. Yang, D.N. Seril, C.S. Yang, Plasma
and  tissue levels of tea catechins in rats and mice during chronic consumption
of  green tea polyphenols, Nutr. Cancer 37 (1) (2000) 41–48.
27] H.S. Kim, M.J. Quon, J.A. Kim, New insights into the mechanisms of
polyphenols beyond antioxidant properties lessons from the green tea
polyphenol epigallocatechin 3-gallate, Redox Biol. 2 (2014) 187–195.
28] L. Kong, W.  Ren, W.  Li, S. Zhao, H. Mi,  R. Wang, Y. Zhang, W.  Wu,  Y. Nan, J. Yu,
Activation of peroxisome proliferator activated receptor alpha ameliorates
ethanol induced steatohepatitis in mice, Lipids Health Dis. 10 (2011) 246.
29] O. Kucera, V. Mezera, A. Moravcova, R. Endlicher, H. Lotkova, Z. Drahota, Z.
Cervinkova, In vitro toxicity of epigallocatechin gallate in rat liver
mitochondria and hepatocytes, Oxid. Med. Cell. Longev. 2015 (2015) 476180.
30] P. Kwiterovich Jr., The metabolic pathways of high-density lipoprotein,
low-density lipoprotein, and triglycerides: a current review, Am.  J. Cardiol. 86
(2000) 5L–10L (12A).
31] J.D. Lambert, R.J. Elias, The antioxidant and pro-oxidant activities of green tea
polyphenols: a role in cancer prevention, Arch. Biochem. Biophys. 5011
(2010) 65–72.
32] J.D. Lambert, M.J. Kennett, S. Sang, K.R. Reuhl, J. Ju, C.S. Yang, Hepatotoxicity of
high oral dose (-)-epigallocatechin-3-gallate in mice, Food Chem. Toxicol. 481
(2010) 409–416.
33] J.D. Lambert, M.J. Lee, L. Diamond, J. Ju, J. Hong, M.  Bose, H.L. Newmark, C.S.
Yang, Dose-dependent levels of epigallocatechin-3-gallate in human colon
cancer cells and mouse plasma and tissues, Drug Metab. Dispos. 341 (2006)
8–11.
34] J.D. Lambert, M.J. Lee, H. Lu, X. Meng, J.J. Hong, D.N. Seril, M.G. Sturgill, C.S.
Yang, Epigallocatechin-3-gallate is absorbed but extensively glucuronidated
following oral administration to mice, J. Nutr. 13312 (2003) 4172–4177.
35] J.D. Lambert, S. Sang, C.S. Yang, Possible controversy over dietary
polyphenols: beneﬁts vs risks, Chem. Res. Toxicol. 204 (2007) 583–585.
36] S.J. Lee, Y. Jia, The effect of bioactive compounds in tea on lipid metabolism
and obesity through regulation of peroxisome proliferator-activated
receptors, Curr. Opin. Lipidol. 261 (2015) 3–9.
37] L. Li, P. Stillemark-Billton, C. Beck, P. Boström, L. Andersson, M.  Rutberg, J.
Ericsson, B. Magnusson, D. Marchesan, A. Ljungberg, J. Borén, S.O. Olofsson,
Epigallocatechin gallate increases the formation of cytosolic lipid droplets
and  decreases the secretion of apoB-100 VLDL, J. Lipid Res. 471 (2006) 67–77.
38] W.  Li, S. Nie, M. Xie, Y. Chen, C. Li, H. Zhang, A major green tea component,
(-)-epigallocatechin-3-gallate: ameliorates doxorubicin-mediated
cardiotoxicity in cardiomyocytes of neonatal rats, J. Agric. Food Chem. 5816
(2010) 8977–8982.
39] C.Y. Liu, C.J. Huang, L.H. Huang, I.J. Chen, J.P. Chiu, C.H. Hsu, Effects of green tea
extract on insulin resistance and glucagon-like peptide 1 in patients with type
2  diabetes and lipid abnormalities: a randomized, double-blinded, and
placebo-controlled trial, PLoS One 93 (2014) e91163.
40] P. Lodhi, N. Tandan, N. Singh, D. Kumar, M.  Kumar, Camellia sinensis L.kuntze
extract ameliorates chronic ethanol-Induced hepatotoxicity in albino rats,
Evid. Based Complement. Alternat. Med. 2014 (2014) 787153.41] J.Q. Ma, J. Ding, H. Zhao, C.M. Liu, Puerarin attenuates carbon
tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by
JNK/c-Jun/CYP7A1 pathway, Basic Clin. Pharmacol. Toxicol. 1155 (2014)
389–395.
[y Reports 3 (2016) 336–345
42] A. Madi Almajwal, M.  Farouk Elsadek, Lipid-lowering and hepatoprotective
effects of Vitis vinifera dried seeds on paracetamol-induced hepatotoxicity in
rats,  Nutr. Res. Pract. 91 (2015) 37–42.
43] K.R. Martin, C.L. Appel, Polyphenols as dietary supplements: a double-edged
sword, Nutr. Diet. Suppl. 2 (2010) 1–12.
44] A. Mahler, S. Mandel, M.  Lorenz, U. Ruegg, E.E. Wanker, M.  Boschmann, F. Paul,
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for
targeted prevention and individualised treatment of neurological diseases?
EPMA J. 41 (2013) 5.
45] D. Mereles, W.  Hunstein, Epigallocatechin-3-gallate EGCG for clinical trials:
more pitfalls than promises? Int. J. Mol. Sci. 129 (2011) 5592–5603.
46] T. Miyazawa, Absorption, metabolism and antioxidative effects of tea catechin
in  humans, Biofactors 131–134 (2000) 55–59.
47] O. Morita, J.B. Kirkpatrick, Y. Tamaki, C.P. Chengelis, M.J. Beck, R.H. Bruner,
Safety assessment of heat-sterilized green tea catech in preparation: a
6-month repeat-dose study in rats, Food Chem. Toxicol. 478 (2009)
1760–1770.
48] A. Murakami, Dose-dependent functionality and toxicity of green tea
polyphenols in experimental rodents, Arch. Biochem. Biophys. 557 (2014)
3–10.
49] R. Ogura, N. Ikeda, K. Yuki, O. Morita, K. Saigo, C. Blackstock, N. Nishiyama, T.
Kasamatsu, Genotoxicity studies on green tea catechin, Food Chem. Toxicol.
466 (2008) 2190–2200.
50] I. Onakpoya, E. Spencer, C. Heneghan, M.  Thompson, The effect of green tea on
blood pressure and lipid proﬁle: a systematic review and meta-analysis of
randomized clinical trials, Nutr. Metab. Cardiovasc. Dis. 248 (2014) 823–836.
51] H. Ortsäter, N. Grankvist, S. Wolfram, N. Kuehn, A. Sjöholm, Diet
supplementation with green tea extract epigallocatechin gallate prevents
progression to glucose intolerance in db/db mice, Nutr. Metab. Lond. 9 (2012)
11.
52] M.  Pae, Z. Ren, M. Meydani, F. Shang, D. Smith, S.N. Meydani, D. Wu,  Dietary
supplementation with high Dose of epigallocatechin-3-gallate promotes
inﬂammatory response in mice, J. Nutr. Biochem. 236 (2012) 526–531.
53] B. Pajak, E. Kania, B. Gajkowska, A. Orzechowski, Lipid rafts mediate
epigallocatechin-3-gallate- and green tea extract-dependent viability of
human colon adenocarcinoma COLO 205 cells clusterin affects lipid
rafts-associated signaling pathways, J. Physiol. Pharmacol. 624 (2011)
449–459.
54] M.H. Pillukat, C. Bester, A. Hensel, M.  Lechtenberg, F. Petereit, S. Beckebaum,
K.M. Müller, H.H. Schmidt, Concentrated green tea extract induces severe
acute hepatitis in a 63-year-old woman—a case report with pharmaceutical
analysis, J. Ethnopharmacol. 1551 (2014) 165–170.
55] R. Raghu, B. Jesudas, G. Bhavani, D. Ezhilarasan, S. Karthikeyan, Silibinin
mitigates zidovudine-induced hepatocellular degenerative changes:
oxidative stress and hyperlipidaemia in rats, Hum. Exp. Toxicol. 3411 (2015)
1031–1042.
56] M.  Reto, C. Almeida, J. Rocha, B. Sepodes, M.  Figueira, Green tea (Camellia
sinensis):  hypocholesterolemic effects in humans and anti-Inﬂammatory
effects in animals, Food Nutr. Sci. 5 (2014) 2185–2194.
57] K. Rezai-Zadeh, D. Shytle, N. Sun, T. Mori, H. Hou, D. Jeanniton, J. Ehrhart, K.
Townsend, J. Zeng, D. Morgan, J. Hardy, T. Town, J. Tan, Green tea
epigallocatechin-3-gallate EGCG modulates amyloid precursor protein
cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice, J.
Neurosci. 2538 (2005) 8807–8814.
58] M.  Roghani, T. Baluchnejadmojarad, Hypoglycemic and hypolipidemic effect
and antioxidant activity of chronic epigallocatechin-gallate in
streptozotocin-diabetic rats, Pathophysiology 17 (1) (2010) 55–59.
59] P. Rudolfová, V. Hanusˇová, L. Skálová, H. Bártíková, P. Matousˇková, I. Bousˇová,
Effect of selected catechins on doxorubicin antiproliferative efﬁcacy and
hepatotoxicity in vitro, Acta Pharm. 642 (2014) 199–209.
60] S. Sae-tan, K.A. Grove, J.D. Lambert, Weight control and prevention of
metabolic syndrome by green tea, Pharmacol. Res. 642 (2011) 146–154.
61] I.G. Saleh, Z. Ali, N. Abe, F.D. Wilson, F.M. Hamada, M.F. Abd-Ellah, L.A. Walker,
I.A. Khan, M.K. Ashfaq, Effect of green tea and its polyphenols on mouse liver,
Fitoterapia 90 (2013) 151–159.
62] S. Sang, J.D. Lambert, J. Hong, S. Tian, M.J. Lee, R.E. Stark, C.T. Ho, C.S. Yang,
Synthesis and structure identiﬁcation of thiol conjugates of
(-)-epigallocatechin gallate and their urinary levels in mice, Chem. Res.
Toxicol. 1811 (2005) 1762–1769.
63] K. Selvakumar, S. Bavithra, S. Suganya, F. Ahmad Bhat, G. Krishnamoorthy, J.
Arunakaran, Effect of quercetin on haematobiochemical and histological
changes in the liver of polychlorined biphenyls-induced adult male wistar
rats,  J. Biomark 2013 (2013) 960125.
65] S.P. Stratton, J.L. Bangert, D.S. Alberts, R.T. Dorr, Dermal toxicity of
topical-epigallocatechin-3-gallate in BALB/c and SKH1 mice, Cancer Lett. 1581
(2000) 47–52.
66] T. Suzuki, A. Takagi, M.  Takahashi, BMC  Proc. 6 (Suppl. 3) (2012) P47.
67] S. Takami, T. Imai, M.  Hasumura, Y.M. Cho, J. Onose, M.  Hirose, Evaluation of
toxicity of green tea catechins with 90-day dietary administration to F344
rats, Food Chem. Toxicol. 466 (2008) 2224–2229.
68] F. Thielecke, M. Boschmann, The potential role of green tea catechins in the
prevention of the metabolic syndrome—a review, Phytochemistry 701 (2009)
11–24.
69] G.L. Tipoe, T.M. Leung, E.C. Liong, T.Y. Lau, M.L. Fung, A.A. Nanji,
Epigallocatechin-3-gallate EGCG reduces liver inﬂammation: oxidative stress
icolog
[
[
[
[
[
[
[
[
[
[
[
ﬁbrosis, J. Nutr. Biochem. 18 (2007) 795–805.
[81] F. Zhou, T. Shen, T. Duan, Y.Y. Xu, S.C. Khor, J. Li, J. Ge, Y.F. Zheng, S. Hsu, J. DE
Stefano, J. Yang, L.H. Xu, X.Q. Zhu, Antioxidant effects of lipophilic teaB. Ramachandran et al. / Tox
and ﬁbrosis in carbon tetrachloride CCl4-induced liver injury in mice,
Toxicology 273 (2010) 45–52.
70] K.H. van het Hof, H.S. de Boer, S.A. Wiseman, N. Lien, J.A. Westrate, L.B. Tijburg,
Consumption of green or black tea does not increase resistance of low-density
lipoprotein to oxidation in humans, Am.  J. Clin. Nutr. 665 (1997) 1125–1132.
71] R.D. Verschoyle, W.P. Steward, A.J. Gescher, Putative cancer chemopreventive
agents of dietary origin-how safe are they? Nutr. Cancer 592 (2007) 152–162.
72] D. Wang, J. Meng, H. Gao, K. Xu, R. Xiao, Y. Zhong, X. Luo, P. Yao, H. Yan, L. Liu,
Evaluation of reproductive and developmental toxicities of Pu-erh black tea
Camellia sinensis var. assamica extract in Sprague Dawley rats, J.
Ethnopharmacol. 1481 (2013) 190–198.
73] D. Wang, J. Meng, K. Xu, R. Xiao, M. Xu, Y. Liu, Y. Zhao, P. Yao, H. Yan, L. Liu,
Evaluation of oral subchronic toxicity of Pu-erh green tea Camellia sinensis
var: assamica extract in Sprague Dawley rats, J. Ethnopharmacol. 1423 (2012)
836–844.
74] D. Wang, Y. Wang, X. Wan, C.S. Yang, J. Zhang, Green tea
polyphenol-epigallocatechin-3-gallate triggered hepatotoxicity in mice:
responses of major antioxidant enzymes and the Nrf2 rescue pathway,
Toxicol. Appl. Pharmacol. 2831 (2015) 65–74.
75] D. Wang, K. Xu, Y. Zhong, X. Luo, R. Xiao, Y. Hou, W.  Bao, W.  Yang, H. Yan, P.
Yao,  L. Liu, Acute and subchronic oral toxicities of Pu-erh black tea extract in
Sprague-Dawley rats, J. Ethnopharmacol. 1341 (2011) 156–164.y Reports 3 (2016) 336–345 345
76] S. Wolfram, Y. Wang, F. Thielecke, Anti-obesity effects of green tea: from
bedside to bench, Mol. Nutr. Food Res. 502 (2006) 176–187.
77] X. Xu, J. Pan, X. Zhou, Amelioration of lipid proﬁle and level of antioxidant
activities by epigallocatechin-gallate in a rat model of atherogenesis, Heart
Lung Circ. 23 (12) (2014) 1194–1201.
78] R.K. Yellapu, V. Mittal, P. Grewal, M.  Fiel, T. Schiano, Acute liver failure caused
by  fat burners and dietary supplements: a case report and literature review,
Can. J. Gastroenterol. 253 (2011) 157–160.
79] L. Zeng, J.M. Holly, C.M. Perks, Effects of physiological levels of the green tea
extract epigallocatechin-3-gallate on breast cancer cells, Front Endocrinol.
(Lausanne) 5 (2014) 61.
80] M.C. Zhen, Q. Wang, X.H. Huang, L.Q. Cao, X.L. Chen, K. Sun, Y.J. Liu, W.  Li, L.J.
Zhang, Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative
damage and preventive effects on carbon tetrachloride-induced hepaticpolyphenols on diethylnitrosamine/phenobarbital-induced
hepatocarcinogenesis in rats, In Vivo 284 (2014) 495–503.
